Eton Pharmaceuticals to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
August 22, 2024 16:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Reports Second Quarter 2024 Financial Results
August 08, 2024 16:01 ET
|
Eton Pharmaceuticals
Product sales and royalty revenue of $9.1 million, representing 40% growth over Q2 2023 and the 14th straight quarter of sequential product sales growthNew drug application (NDA) for ET-400 accepted...
Eton Pharmaceuticals to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024
July 30, 2024 17:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., July 30, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing...
Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
July 15, 2024 16:05 ET
|
Eton Pharmaceuticals
- Prescription Drug User Fee Act (PDUFA) target action date is February 28, 2025 - - Product has patent protection through 2043 - DEER PARK, Ill., July 15, 2024 (GLOBE NEWSWIRE) -- Eton...
Eton Pharmaceuticals Reports First Quarter 2024 Financial Results
May 09, 2024 16:01 ET
|
Eton Pharmaceuticals
• Q1 2024 revenue of $8.0 million, representing 50% growth over Q1 2023 and the 13th straight quarter of sequential product sales growth• Acquired PKU GOLIKE®, launched Nitisinone, and submitted a...
Eton Pharmaceuticals to Present at the Citizens JMP Life Sciences Conference
May 01, 2024 16:05 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., May 01, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Announces Submission to FDA of New Drug Application for ET-400 (Hydrocortisone Oral Solution)
April 30, 2024 07:00 ET
|
Eton Pharmaceuticals
- Company anticipates 10-month review for potential approval in Q1 2025 -- Eton expects ET-400 and Alkindi Sprinkle® to achieve potential combined peak sales of more than $50 million annually --...
Eton Pharmaceuticals to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024
April 29, 2024 16:30 ET
|
Eton Pharmaceuticals
DEER PARK, Ill., April 29, 2024 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (“Eton” or the "Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and...
Eton Pharmaceuticals Announces Acquisition of PKU GOLIKE® for Phenylketonuria
March 22, 2024 02:00 ET
|
Eton Pharmaceuticals
PKU GOLIKE® is a commercial ultra-rare disease medical formula complementary to Eton's existing metabolic franchise and specialty call pointTransaction is expected to be accretive to 2024...
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results
March 14, 2024 16:01 ET
|
Eton Pharmaceuticals
Q4 2023 revenue of $7.3 million, representing a 109% increase from Q4 2022, marking the twelfth consecutive quarter of sequential product sales growthFull year 2023 revenues reached $31.6 million with...